A brief mention12 Feb 2022 17:18
Potential clinical applications of phytopharmaceuticals for the in-patient management of coagulopathies in COVID-19
Published yesterday, a brief mention
https://onlinelibrary.wiley.com/doi/full/10.1002/ptr.7408
Recent studies have focused on discovering natural products as active supplements or as replacements for ongoing synthetic antithrombotic drugs (Zhao et al., 2020). The active ingredients of natural products (e.g., extracts of traditional herbs and medicinal plants), the traditional system of medicine used in several countries (e.g., Chinese medicines), the Indian system of ancient medicine (Ayurveda), and functional foods have shown remarkable antithrombotic properties in vitro and in pre-clinical studies (Cordier et al., 2012; Gogoi, Ramani, Bhartari, Chattopadhyay, & Mukherjee, 2019; Li, Liang, & Sun, 2019; Memariani, Moeini, Hamedi, Gorji, & Mozaffarpur, 2018; O'Kennedy, Raederstorff, & Duttaroy, 2017; Sen & Chakraborty, 2017; Yamamoto et al., 2018). The significant advantages of using plant-derived natural products for therapeutic treatment have been realized because several of these compounds (as crude extracts or as partially purified plant extracts) are comprised of multiple components. Each component may target different factors in the coagulation cascade and their synergistic interactions may enhance their therapeutic efficacies (Gogoi et al., 2018,b, 2020). Moreover, numerous intriguing properties of natural products (e.g., rapid absorption when ingested by the oral route, marginal side-effect(s) in the gastrointestinal tract, and their non-immunogenicity) suggest their strong efficacy and safety (Fuentes & Palomo, 2014).
Sign In
Follow the stocks
